ustekinumab

Home
Ligands
ustekinumab

GtoPdb Ligand ID: 6885

Synonyms: CNTO-1275 | L04AC05 | Stelara® | TT-20

ustekinumab is an approved drug (FDA (2009), EMA (2009))

Comment: Ustekinumab suppresses the immunomodulatory actions of both IL-12 and IL-23 on T-cell sub-populations. It binds to the common p40 subunit (IL12B) shared by these cytokines.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Qyuns Therapeutics have a potential ustekinumab biosimilar (QX001S) in Phase 1 evaluation for psoriasis (trial registry number ChiCTR1900022127).

No information available.

No information available.

Summary of Clinical Use
Used to treat adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and is approved in the US to treat psoriatic arthritis.

Summary of Clinical Use

Used to treat adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and is approved in the US to treat psoriatic arthritis.

Mechanism Of Action and Pharmacodynamic Effects
Ustekinumab binds to the IL-12B component of the dimeric cytokines IL-12 and IL-23. This action supresses the activation of certain T-cells, thereby dampening the immune response.

Mechanism Of Action and Pharmacodynamic Effects

Ustekinumab binds to the IL-12B component of the dimeric cytokines IL-12 and IL-23. This action supresses the activation of certain T-cells, thereby dampening the immune response.

External links
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA)

External links

For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
Drugs.com
European Medicines Agency (EMA)